Previous close | 0.7860 |
Open | 0.7909 |
Bid | 0.6946 x 100 |
Ask | 0.7906 x 100 |
Day's range | 0.7200 - 0.7950 |
52-week range | 0.7200 - 6.0000 |
Volume | |
Avg. volume | 106,493 |
Market cap | 16.124M |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it allowed pharmaceutical companies like Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) to develop their groundbreaking vaccines in record time. By the looks of it, this was only the beginning of the healthcare revolution that mRNA triggered. Mainz Biomed N.V. (NASDAQ: MYNZ) to revolutionize c
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: JNJ) are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk. The expiration of patents for one or more leading branded products for a company means opening the door to competitors to sell copycats of those drugs, often at a competitive price. But, as always, pharmaceutical companies do their best
Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).